Application Effect of Comprehensive Noise Reduction Technology in Outpatients with Vitiligo: A Retrospective Study.

OBJECTIVE: Noise is a kind of perceived public nuisance that is closely related to people's subjective feelings and lives. This study explores the clinical application effect of comprehensive noise reduction technology in outpatients with vitiligo. METHODS: A total of 76 patients with vitiligo were selected in the Department of Dermatology at Baoding No. 2 Central Hospital from January 2020 to January 2021, as the control group (CG), receiving 5S management mode, and 80 patients with vitiligo from February 2021 to October 2022 were selected as the study group (SG), receiving comprehensive noise reduction technology combined with the 5S management mode for this retrospective study. The effects of different management modes on these patients were observed. RESULTS: SG had higher nursing quality scores in service attitude, service initiative, communication skills, environmental management and item management and overtly a lower noise level than CG (all P < 0.001). The Hamilton Anxiety Scale (HAMA) scores of the two groups at the end of treatment were significantly lower than those on admission (P < 0.05), with SG showing a lower score than CG (P < 0.001). Correlation analysis showed that noise levels and HAMA scores had a positive correlation (r = 0.423, P < 0.001). Patients with negative feelings about medical treatment caused by various noise sources in SG were obviously less than those in CG (P < 0.05). Both the groups had a statistical difference in overall satisfaction (P < 0.05). CONCLUSION: The investigation and data analysis demonstrated that comprehensive noise reduction in outpatients with vitiligo had a considerable effect. This technology can standardise the behaviour of medical staff, enhance nursing quality, reduce noise levels and alleviate patients' anxiety and improve their satisfaction. It has great benefits for the outpatient environment and patients.

Serum level of advanced oxidation protein products (AOPPs) in patients with Henoch-Schonlein purpura and its relationship with aberrant glycosylation of IgA1 and Cosmc mRNA expression.

BACKGROUND: Henoch-Schonlein purpura (HSP) is a systemic small vessel vasculitis that is mainly caused by IgA1-type immune complex deposition. Advanced oxidation protein products (AOPPs) are specific markers of protein oxidation. OBJECTIVE: To explore the role of AOPPs in the pathogenesis of HSP. METHODS: There are 51 HSP patients who were divided into four subgroups: (i) skin type - 20 cases; (ii) joint type - 8 cases; (iii) abdominal type - 12 cases; (iv) renal type - 11 cases; and 18 healthy volunteers were enrolled as controls. The serum levels of AOPPs and Gd-IgA1 were quantified by an HAA-lectin-based ELISA. The Cosmc mRNA expression in peripheral B lymphocytes was measured by RT-PCR. RESULTS: 1. Advanced oxidation protein products in different subgroups of HSP patients are all higher than the controls, while the renal-type subgroup is the highest and the skin-type subgroup is the lowest. 2. Spearman correlation analysis shows that: (i) AOPPs and Gd-IgA1 in HSP patients are positively correlated; both of them are positively correlated with the disease severity scores; (ii) AOPPs are negatively correlated with the relative expression value (RQ) of Cosmc mRNA. CONCLUSION: Advanced oxidation protein products play an important role in the pathogenesis of HSP, especially in renal-type patients.

A novel anti-platelet aggregation tripeptide from Agkistrodon acutus venom: isolation and characterization.

AAP, a tripeptide that inhibited rabbit platelet aggregation, was isolated from Agkistrodon acutus venom by ion-exchange, gel filtration and reverse-phase chromatography. Amino acid sequences which determined mainly by amino acid analyses and NMR spectroscopy indicated it was a tripeptide including pyroglutamic acid, asparagine and tryptophane residues. The ESMS experiment assigned a molecular weight of 429 Da. AAP inhibited rabbit platelet aggregation induced by ADP, PAF-acether, collagen and thrombin, the IC(50)s were 178 microM, 332 microM, 179 microM and 203 microM, respectively. AAP also inhibited thrombus formation in vivo thrombosis model and prevented the combination between fibrinogen and GP IIb/IIIa. Besides, AAP was not toxic after intravenous injection into mice at a higher dose. Those studies might be helpful to delineate unknown mechanisms involved in platelet aggregation and serve as a model for developing antithrombotic agents.

Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).

OBJECTIVES: The aim was to test a newly discovered oligopeptide, pENW (pGlu-Asn-Trp), for its anticoagulant and antithrombotic activity in vivo, and try to investigate its underlying mechanisms. METHODS: We measured coagulation time by the glass slide method and bleeding time by cutting of mice tails. The thrombosis models employed here included an arterio-venous shunt model and inferior vena ligation model. An ELISA (enzyme-linked immunosorbent assay) was used to analyse t-PA/PAI (tissue-type plasminogen activator/plasminogen activator inhibitor) in the blood drawn from the rats with thrombosis. The ultrastructural changes of the endothelium in the vessels developing thrombosis were observed under a transmission electron microscope. KEY FINDINGS: We found that pENW-treated mice exhibited a prolonged coagulation time in a dose-dependent manner, but not an extended haemorrhage time. On the other hand, pENW significantly inhibited thrombus formation in both arterio-venous shunt models and inferior vena ligation models. Plasma t-PA/PAI was significantly higher as measured by ELISA. Transmission electron microscope photos of pENW-treated groups also displayed a better condition than model controls, with less erythrocytes in the vascular lumens. In addition, pENW concentration-dependently inhibited aggregation of platelets induced by ADP (adenosine 5'-diphosphate sodium salt) in rabbit platelet-rich plasma. CONCLUSIONS: These findings support the suggestion that pENW possesses antithrombotic activity and could be a promising drug in the prevention and treatment of unwanted clot formation.